| Business Summary | | OraPharma,
Inc.
is
a
specialty
pharmaceutical
company
that
is
engaged
in
discovering,
developing
and
commercializing
pharmaceutical
products
for
oral
healthcare.
In
February
2001,
the
Company
received
approval
from
the
United
States
Food
and
Drug
Administration
to
market
the
Company's
first
product,
Arestin.
The
Company's
other
product
candidates,
which
are
in
earlier
stages
of
development,
include
a
compound
for
the
treatment
of
oral
mucositis,
an
agent
for
bone
and
tissue
regeneration,
a
second
treatment
approach
for
periodontitis
as
a
follow-on
to
Arestin
and
a
dental
trauma
treatment
using
Arestin.
OraPharma
is
directing
its
research
and
development
programs
at
further
establishing
a
presence
in
oral
health
care
pharmaceuticals
and
expanding
the
use
of
its
core
technology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OraPharma,
Inc.
is
a
specialty
pharmaceutical
company
that
is
engaged
in
discovering,
developing
and
commercializing
pharmaceutical
products
for
oral
healthcare.
Its
first
product
is
for
the
treatment
of
adult
periodontitis.
For
the
six
months
ended
6/30/01,
revenue
totaled
$2
million,
up
from
$0.
Net
loss
totaled
$13.5
million,
up
from
$4.3
million.
Results
reflect
initial
revenues
from
the
sale
of
Arestin,
offset
by
increased
sales
and
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Kishbauch, 51 Pres,
CEO, Director | $320K | -- | James Ratigan, 52 CFO,
Exec. VP, Sec. | 236K | $508K | J. Ronald Lawter, Ph.D., 58 Exec.
VP, CTO, Chief Scientific Officer | 229K | 43K | Joseph Zack, 49 VP
of Sales and Marketing | 214K | 103K | Mark Carbeau, 40 VP,
Corp. Devel. | 272K | 281K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|